LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

75.67 1.69

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

72.28

Max

76.12

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+14.64% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

232M

12B

Ankstesnė atidarymo kaina

73.98

Ankstesnė uždarymo kaina

75.67

Naujienos nuotaikos

By Acuity

100%

0%

365 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-20 23:07; UTC

Rinkos pokalbiai

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

2025-11-20 22:22; UTC

Rinkos pokalbiai

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

2025-11-20 22:08; UTC

Rinkos pokalbiai

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

2025-11-20 21:57; UTC

Uždarbis

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

2025-11-20 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-11-20 21:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-11-20 21:31; UTC

Uždarbis

Nvidia's Strong Results Show AI Fears Are Premature -- Update

2025-11-20 21:23; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

2025-11-20 21:07; UTC

Uždarbis

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025-11-20 21:06; UTC

Uždarbis

Webull 3Q Rev $156.9M >BULL

2025-11-20 21:06; UTC

Uždarbis

Webull 3Q EPS 7c >BULL

2025-11-20 21:05; UTC

Uždarbis

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

2025-11-20 21:04; UTC

Uždarbis

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

2025-11-20 21:04; UTC

Uždarbis

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

2025-11-20 21:04; UTC

Uždarbis

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

2025-11-20 21:00; UTC

Uždarbis

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Rev $21B-$21.19B >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit 1Q Consumer Rev $894M

2025-11-20 21:00; UTC

Uždarbis

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 Guidance

2025-11-20 21:00; UTC

Uždarbis

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

2025-11-20 21:00; UTC

Uždarbis

Intuit 1Q Global Business Solutions Rev $3B

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

14.64% į viršų

12 mėnesių prognozė

Vidutinis 84.83 USD  14.64%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

17

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

365 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat